恒瑞医药(01276.HK)盘中涨超18%，股价突破70港元，创历史新高，公司SHR-2173注射液获批临床，截至目前，SHR-2173 注射液相关项目累计研发投入约6,407万元。

Core Viewpoint - Heng Rui Pharmaceutical (01276.HK) experienced a significant stock price increase of over 18%, surpassing 70 HKD, marking a historical high due to the approval of its SHR-2173 injection for clinical use [1] Company Summary - The company has invested approximately 64.07 million yuan in the research and development of the SHR-2173 injection project to date [1]